// App-Quantinova.ai

: ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)

Researchers

Presenter

  • Mario Campone

Principal Investigators

  • Angelica Fasolo

  • Jose Lopez-Martin

  • Tae Min Kim

  • Warren Mason

  • Ralf-Dieter Hofheinz

  • Jean-Yves Blay

  • Daniel Cho

  • Anas Gazzah

  • Carlos Gomez-Roca

  • Jeffrey Yachnin

  • Aislyn Boran

  • Paul Burgess

  • Ilan Palanichamy

  • Eduard Gasal

  • Vivek Subbiah

Medical Centers

  • Institut de Cancerologie de l'Ouest Paul Papin, Angers, France

  • Fondazione IRCCS “Istituto Nazionale dei Tumori”, Unit of New Drugs & Innovative Therapies, Department of Medical Oncology, Milano, Italy

  • Medical Oncology Department. Hospital 12 de Octubre, Madrid, Spain

  • Seoul National University Cancer Research Institute, Seoul, Republic of Korea

  • Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

  • University Hospital Mannheim, Mannheim, Germany

  • Department of Medical Oncology, Centre Leon Berard, Lyon, Languedoc-Roussillon, France

  • Cancer Institute, NYU Langone Medical Center, New York, NY

  • Drug Development Department, Gustave Roussy, Cancer Campus, Grand Paris, Villejuif, France

  • Biostatistics Unit, Institut Claudius Regaud-Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole, Toulouse, France

  • Karolinska University Hospita,l Department of Oncology, Stockholm, Sweden

  • Novartis, Morris Plains, NJ.

  • The University of Texas, MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics, Houston, TX, USA

Locations

  • France

  • Italy

  • Spain

  • Canada

  • Germany

  • United States

  • Sweden

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • High-Grade Gliomas

  • Low-grade gliomas

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

Drug/Treatment

  • Dabrafenib Mesylate

  • Trametinib

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved